In May 2022, Lillys Mounjaro (tirzepatide) bagged FDA approval as the first and only approved dual agonist for the treatment of T2DM
Some GLP-1s are approved for kids as young as 12
Data in weight loss Most of the existing empirical data on weight loss with GLP-1 agonists come from studies of individuals who are overweight or obese, with or without type 2 diabetes, rather than from studies using these agents to counteract iatrogenic weight gain
A lower 4mg weekly dose also resulted in impressive weight loss results, with an average loss of 17% over 48 weeks and: 92% of participants lost at least 5% of their starting body weight 75% lost at least 10% of their body weight 60% lost at least 15% of their starting weight Retatrutide vs Mounjaro In clinical trials, the active ingredient in Mounjaro, tirzepatide, results in an average weight loss of 22.5% at the highest 15mg per week dose over 72 weeks
Retatrutides triple-agonist action helps regulate several aspects of metabolism and appetite
The picture on Trustpilot is much more flattering, with an impressive 4.7 out of 5 stars from over 4,000 customer reviews
